Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hypha LabsFUNI 3-Year EBITDA Growth Rate is 5.40% as of Mar. 2026, which is 77% below its 10-year median of 23.60. The stock has 2 warning signs investors should review. Among 166 Medical Diagnostics & Research companies, Hypha Labs ranks worse than 55.42% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 5.40% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 2.90% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 25.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Hypha Labs was 67.10% per year. The lowest was -220.30% per year. And the median was 23.60% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Hypha Labs 3-Year EBITDA Growth Rate Related Terms
FUNI vs ISPC, BIAF, IVRO: 3-Year EBITDA Growth Rate Comparison
For the Diagnostics & Research subindustry, Hypha Labs's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hypha Labs 3-Year EBITDA Growth Rate vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Hypha Labs's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Hypha Labs's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 5.40% mean?
Hypha Labs (FUNI) has a 3-Year EBITDA Growth Rate of 5.40% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Hypha Labs and its competitors. This is 77% below median its historical median of 23.60. According to the industry distribution chart, Hypha Labs ranks #92 out of 166 companies in the Medical Diagnostics & Research industry, placing it in the top 55.4%.
Is Hypha Labs' 3-Year EBITDA Growth Rate too high?
Hypha Labs' current 3-Year EBITDA Growth Rate of 5.40% is 77% below median its 10-year median of 23.60. The Medical Diagnostics & Research industry median 3-Year EBITDA Growth Rate is 10.80. Hypha Labs' value of 5.40% is 50% below this industry median. Based on the distribution chart, Hypha Labs ranks #92 out of 166 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint.
How does Hypha Labs' 3-Year EBITDA Growth Rate compare to ISPC and BIAF?
According to the Medical Diagnostics & Research industry distribution chart, Hypha Labs ranks #92 out of 166 companies for 3-Year EBITDA Growth Rate. This places Hypha Labs in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 10.80. Hypha Labs' value of 5.40% is 50% below this benchmark. While the company's 10-year median is 23.60 vs. the industry median of 10.80, Hypha Labs has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Diagnostics & Research company?
The median 3-Year EBITDA Growth Rate among Medical Diagnostics & Research companies is 10.80, based on 166 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hypha Labs's current 3-Year EBITDA Growth Rate of 5.40% is 50% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Hypha Labs and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year EBITDA Growth Rate is 10.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hypha Labs's current 3-Year EBITDA Growth Rate is 5.40%, which is 77% below median its own 10-year median of 23.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hypha Labs stock overvalued right now?
Hypha Labs (FUNI) has a current 3-Year EBITDA Growth Rate of 5.40%. The current 3-Year EBITDA Growth Rate is 5.40%, which is 77% below median its 10-year median of 23.60 and 50% below the Medical Diagnostics & Research industry median of 10.80. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Hypha Labs (FUNI), the current 3-Year EBITDA Growth Rate is 5.40% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Hypha Labs Inc engaged in the research, development, and commercialization of the Hypha Micropearl accelerator, an in-home, web-based, computer-controlled bioreactor designed to accelerate the production of nutritionally beneficial mushrooms for human consumption. The Company's easy-to-use device, together with replaceable cartridges ordered through its exclusive app, safely and effectively produced enriched mycelium of functional mushrooms, or Micropearls, in eight days. These Micropearls contained active mushroom ingredients in a concentrated, easy-to-handle, tasteless, and odorless form that could be incorporated into various foods and beverages without altering flavor.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FUNI has been successfully added to your 
